Patents by Inventor David R. Lancia

David R. Lancia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for activating pyruvate kinase
    Patent number: 10836771
    Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: November 17, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
  • Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
    Patent number: 10836741
    Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4?, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Valo Early Discovery, Inc.
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David R. Lancia, Jr.
  • 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 10829461
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 10, 2020
    Assignee: Valo Early Discovery, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 10829462
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: November 10, 2020
    Assignee: Valo Early Discovery, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin, Kenneth W. Bair
  • [6,6] fused bicyclic HDAC8 inhibitors
    Patent number: 10829460
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein, useful as inhibitors of zinc-dependent histone deacetylases (HDACs) and in the treatment of diseases or disorders associated with HDACs.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: November 10, 2020
    Assignee: Valo Early Discovery, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Thomason, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair
  • COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
    Publication number: 20200347025
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 5, 2020
    Inventors: Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
  • 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 10822316
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: November 3, 2020
    Assignee: Valo Early Discovery, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
    Publication number: 20200331847
    Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
    Type: Application
    Filed: November 20, 2019
    Publication date: October 22, 2020
    Inventors: Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
  • Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10807976
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: October 20, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Compounds and compositions for inhibition of FASN
    Patent number: 10800750
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 13, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20200253939
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200223822
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Activating pyruvate kinase R
    Patent number: 10675274
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: June 9, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20200129485
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 30, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Forsyth Sanjeev, Kelly J. Patrick, Madhu Mondal, Maria Ribadeneira, Schroeder Patricia
  • FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200115343
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • ACTIVATING PYRUVATE KINASE R
    Publication number: 20200085798
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 19, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20200087280
    Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4?, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 19, 2020
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, David R. Lancia, JR.
  • ACTIVATING PYRUVATE KINASE R AND MUTANTS THEREOF
    Publication number: 20200087309
    Abstract: The disclosure provides chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).
    Type: Application
    Filed: September 19, 2019
    Publication date: March 19, 2020
    Inventors: David R. Lancia, JR., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
  • METHODS USING HDAC11 INHIBITORS
    Publication number: 20200079744
    Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 12, 2020
    Inventors: Jennifer Lee, Nicholas Barczak, Jaime A. Escobedo, Chiara Conti, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Xiaozhang Zheng
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20200069643
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 5, 2020
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, Jr., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG